BR112012025567A2 - peptídeos de cdca5 e vacinas que incluem os mesmos - Google Patents
peptídeos de cdca5 e vacinas que incluem os mesmosInfo
- Publication number
- BR112012025567A2 BR112012025567A2 BR112012025567A BR112012025567A BR112012025567A2 BR 112012025567 A2 BR112012025567 A2 BR 112012025567A2 BR 112012025567 A BR112012025567 A BR 112012025567A BR 112012025567 A BR112012025567 A BR 112012025567A BR 112012025567 A2 BR112012025567 A2 BR 112012025567A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- peptides
- nucleic acids
- vaccines
- mentioned
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
peptídeos de cdca5 e vacinas que incluem os mesmos a presente invenção refere-se a peptídeos isolados derivados de seq id no: 21 e fragmentos dos mesmos que se ligam a um antígeno hla e induzem a linfócitos t citotóxicos (cytotoxic t lymphocytes - ctl ) e , assim, são adequados para uso no contexto de imunoterapia de câncer, mais particularmente vacinas de câncer , são descritos aqui. os peptídeos da invenção abrangem as sequências de aminoácidos mencionados acima e versões modificadas das mesmas nas quais um , dois ou vários aminoácidos são substituídos , deletados, inseridos ou adicionados, contanto que tais versões modificados retenham a lilgação ao hla e/ou indutibilidade de cti das sequências originais . ainda proporcionados são ácidos nucleicos que codificam qualquer um dos peptídeos mencionados acima , bem como agentes , substâncias e/ou composições farmacêuticas que incluem ou incorporam qualquer um dos peptídeos ou ácidos nucleicos antes mencionados. os peptídeos, ácidos nucleicos , agentes farmacêuticos, substâncias e composições da presente invenção encontram utilidade particular no tratamento de cânceres e tumores incluinodo, por exemplo, aml, câncer de bexiga, câncer de mama, câncer cervical, carcinoma colangiocelular, cml, câncer cólon-retal câncer de esôfago, câncer gástrico, câncer gástrico do tipo difuso, cânccer de pulmão, linfoma, câncer de próstata, sclc e tumor de tecidos moles
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32267610P | 2010-04-09 | 2010-04-09 | |
PCT/JP2011/002078 WO2011125334A1 (en) | 2010-04-09 | 2011-04-07 | Cdca5 peptides and vaccines including the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012025567A2 true BR112012025567A2 (pt) | 2019-09-24 |
Family
ID=44762304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012025567A BR112012025567A2 (pt) | 2010-04-09 | 2011-04-07 | peptídeos de cdca5 e vacinas que incluem os mesmos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20130108664A1 (pt) |
EP (1) | EP2556084A4 (pt) |
JP (1) | JP2013523084A (pt) |
KR (1) | KR20130043627A (pt) |
CN (1) | CN102947325B (pt) |
AU (1) | AU2011236397A1 (pt) |
BR (1) | BR112012025567A2 (pt) |
CA (1) | CA2795534A1 (pt) |
MX (1) | MX2012011668A (pt) |
RU (1) | RU2012147590A (pt) |
SG (2) | SG183945A1 (pt) |
TW (1) | TW201138806A (pt) |
WO (1) | WO2011125334A1 (pt) |
ZA (1) | ZA201207416B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016502499A (ja) * | 2012-12-04 | 2016-01-28 | オンコセラピー・サイエンス株式会社 | Sema5bペプチドおよびそれを含むワクチン |
WO2014106886A1 (en) * | 2013-01-07 | 2014-07-10 | Oncotherapy Science, Inc. | Cdca5 peptides and vaccines containing the same |
TW201636358A (zh) * | 2014-12-09 | 2016-10-16 | 腫瘤療法 科學股份有限公司 | 對於th1細胞之gpc3抗原決定位胜肽及含此之疫苗 |
CN107619835A (zh) * | 2017-05-11 | 2018-01-23 | 广东医科大学 | Cdca5在胃癌中的表达载体及其构建方法及cdca5在胃癌中特异干扰片段 |
CA3069047A1 (en) * | 2017-07-12 | 2019-01-17 | Nouscom Ag | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers |
CN109355394A (zh) * | 2018-12-28 | 2019-02-19 | 江苏省人民医院(南京医科大学第附属医院) | 癌-睾丸抗原cdca5作为食管鳞癌预后标志物及治疗靶点 |
SI3840767T1 (sl) * | 2019-05-29 | 2024-04-30 | Hubro Therapeutics As | Peptidi |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002320089A1 (en) * | 2001-06-15 | 2003-01-02 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長cDNA |
ATE531729T1 (de) * | 2002-09-12 | 2011-11-15 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
TWI434853B (zh) * | 2007-04-11 | 2014-04-21 | Oncotherapy Science Inc | 腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗 |
KR20100075858A (ko) * | 2007-08-24 | 2010-07-05 | 온코세라피 사이언스 가부시키가이샤 | 암 관련 유전자,cdca5,epha7,stk31 및 wdhd1 |
TW200932260A (en) * | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
-
2011
- 2011-04-07 SG SG2012066221A patent/SG183945A1/en unknown
- 2011-04-07 CA CA2795534A patent/CA2795534A1/en not_active Abandoned
- 2011-04-07 WO PCT/JP2011/002078 patent/WO2011125334A1/en active Application Filing
- 2011-04-07 JP JP2012546271A patent/JP2013523084A/ja not_active Withdrawn
- 2011-04-07 CN CN201180028644.6A patent/CN102947325B/zh not_active Expired - Fee Related
- 2011-04-07 KR KR1020127028423A patent/KR20130043627A/ko not_active Application Discontinuation
- 2011-04-07 EP EP11765236.2A patent/EP2556084A4/en not_active Withdrawn
- 2011-04-07 BR BR112012025567A patent/BR112012025567A2/pt not_active IP Right Cessation
- 2011-04-07 AU AU2011236397A patent/AU2011236397A1/en not_active Abandoned
- 2011-04-07 SG SG10201502791YA patent/SG10201502791YA/en unknown
- 2011-04-07 RU RU2012147590/10A patent/RU2012147590A/ru not_active Application Discontinuation
- 2011-04-07 US US13/639,935 patent/US20130108664A1/en not_active Abandoned
- 2011-04-07 MX MX2012011668A patent/MX2012011668A/es not_active Application Discontinuation
- 2011-04-08 TW TW100112188A patent/TW201138806A/zh unknown
-
2012
- 2012-10-03 ZA ZA2012/07416A patent/ZA201207416B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2556084A4 (en) | 2013-08-14 |
US20130108664A1 (en) | 2013-05-02 |
SG183945A1 (en) | 2012-10-30 |
MX2012011668A (es) | 2012-12-17 |
CN102947325A (zh) | 2013-02-27 |
AU2011236397A1 (en) | 2012-11-01 |
TW201138806A (en) | 2011-11-16 |
JP2013523084A (ja) | 2013-06-17 |
RU2012147590A (ru) | 2014-05-20 |
ZA201207416B (en) | 2013-06-26 |
WO2011125334A1 (en) | 2011-10-13 |
CN102947325B (zh) | 2015-04-01 |
KR20130043627A (ko) | 2013-04-30 |
SG10201502791YA (en) | 2015-05-28 |
CA2795534A1 (en) | 2011-10-13 |
EP2556084A1 (en) | 2013-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500484A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
EA201201306A1 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
BR112012025567A2 (pt) | peptídeos de cdca5 e vacinas que incluem os mesmos | |
MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
MX2014001675A (es) | Peptidos de mphosph1 y vacunas que incluyen los mismos. | |
MX2013014489A (es) | Peptidos sema5b y vacunas que incluyen los mismos. | |
BR112012022641A2 (pt) | peptídeos hjurp e vacinas que incluem os mesmos | |
SG10201408245WA (en) | Tmem22 peptides and vaccines including the same | |
MX2020005188A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
MX342000B (es) | Peptidos ect2 y vacunas que los incluyen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |